Galapagos

Vitalnext B.V., founded in 2013 and based in Amersfoort, the Netherlands, focuses on developing products that provide evidence-based health benefits for the aging population. The company offers a range of products, including Promanna, which comprises orally administered active small molecules; L-Proline, known for its positive effects on organisms under stress; D-Mannitol, a sugar with historical health benefits; and Vital01, designed to address malnutrition in the elderly. Vitalnext aims to enhance healthy aging, responding to the growing global demand for products that promote prolonged well-being. Their most advanced offering is an innovative medical nutrition product that not only helps improve body weight in malnourished individuals but also enhances body composition by increasing muscle mass. The company commercializes its products through distribution and licensing agreements with specialized partners, bridging the gap between life sciences and consumer health products.

Cangenix provides a range of crystallographic and biophysical techniques, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), using tailored biological reagents to accelerate the understanding of compound-target interactions and utilize structural, kinetic and thermodynamic data to inform drug design.

Argenta Discovery is a privately held contract research drug discovery company.

ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. With more than 300 people employed by the Company, ProStrakan is headquartered in Scotland with commercial operations throughout the rest of the UK and continental Europe and a US head office. The Company's Development group is located in Galashiels, Scotland and Bedminster, New Jersey, US.

Inpharmatica is a company focused on enhancing drug discovery through predictive informatics, specifically in the fields of medicinal chemistry and ADME. Established in 1998, it operates from locations in London and Cambridge, employing approximately 35 professionals. The company utilizes its proprietary technologies to improve the efficiency and productivity of drug discovery processes, offering a comprehensive range of services that cover the entire research spectrum, from target identification to candidate selection. Inpharmatica's innovative informatics approaches analyze the relationships between protein structure and function, aiding medicinal companies in identifying viable drug targets for further development. Its technologies and services are utilized by major discovery laboratories globally, allowing clients to either access complete end-to-end solutions or select specific components tailored to their needs.

BioFocus DPI Ltd develops gene-to-candidate drug discovery products and provides services to biotech, pharma, and patient and non-profit organizations.